Noticias

Noticias

  • Título: It is now confirmed: CAS risks and challenges are all upfront, but the long-term stroke prevention benefit that is very bit as good as that of CEA
  • Fecha: 05-04-2016

  • Frank J Criado, MD, FACS, FSVM


    The “noise” and controversy about CAS and which one is better CAS or CEA continues unabated… although things are finally beginning to change and move forward with many noted experts predicting that carotid stenting will evolve into an intervention that is equal to CEA in all respects. But that might describe tomorrow, not today.

    It is still widely acknowledged that CAS carries a small but definitely higher risk of stroke within the first 30 days, both during the procedure and afterwards. And this is especially so in certain patient subsets such as the elderly, symptomatic and complex extensive lesions and those with arch-related issues of anatomy and atherosclerotic disease.

    And now to the point of this blog post:

    Principal Investigator Thomas Brott presented and then published early this year (N Engl J Med 2016;374:1021-31) the 10-year results of their landmark CREST trial. The study included 2,502 patients at 117 centers in the U.S. and Canada, and the subjects were followed for 10 years. Their analysis found that there was equal patient benefit from both CAS and CEA with an approximately 7% risk of stroke (about 1% per year). And the parity held for all patient subsets, including younger and older individuals, men and women, patients with a history of prior stroke and for those without such history.



  • Fuente: endovascular.es